Stem cells and antibodies for early Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This study tests whether human stem cells, combined with your existing Alzheimer's medication (Leqembi or Kisunla), can help slow memory loss and improve daily functioning in people with mild cognitive impairment or early Alzheimer's. You would receive a stem cell infusion as an add-on to your current treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 55–90 years old
- Diagnosed with mild cognitive impairment or mild Alzheimer's dementia
- Already taking Leqembi (lecanemab) or Kisunla (donanemab) for at least 6 months before the study infusion
- Able to give informed consent on your own
- Have a family member or close friend who can answer questions about your daily activities throughout the study
- Willing to undergo a stem cell infusion procedure
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a stem cell treatment for people with early-stage Alzheimer's disease. It aims to see if the treatment can help slow memory loss or other symptoms. You must have a specific blood test showing inflammation in the body to qualify.
This trial tests a new stem cell treatment (called RB-ADSCs) that is injected into the fluid around your brain. It aims to see if these cells can help slow down memory loss and thinking problems in people with mild to moderate Alzheimer's disease.
This trial tests lecanemab, an infusion medicine that targets amyloid protein buildup in the brain, in people with mild cognitive impairment or mild Alzheimer's disease. Researchers will track how well it works and study how it affects your body's proteins using advanced lab tests.
This study tests whether tiny particles called exosomes derived from neural stem cells can help slow memory loss and thinking problems in people with Alzheimer's disease that started before age 65. The treatment is given through the nose and aims to reduce harmful proteins in the brain.
This study tests how lecanemab works in people with early Alzheimer’s, including those with mild dementia or mild memory problems. It aims to see if the drug can help clear brain plaques and slow down symptoms.
This trial tests a monoclonal antibody therapy—a lab-made protein—to see if it can slow Alzheimer's symptoms. You may qualify if you have early Alzheimer's or mild cognitive impairment with a positive PET scan, and you can't have other major health issues like uncontrolled diabetes or heart problems.
Hear when a new Mild Cognitive Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.